Molecular diagnostics company BillionToOne reported Q4 revenue of $96.1 million, more than double year‑ago sales, and raised full‑year 2026 guidance to $430–$445 million. The company said it will become in‑network with UnitedHealthcare starting April 1, a move expected to improve patient access and average selling price for its prenatal and oncology tests. Management cited expansion of the prenatal and oncology sales forces, new product launches and payer contracting as growth drivers. The results reflect accelerating commercial adoption of high‑throughput cfDNA testing and highlight payer access as a near‑term lever for diagnostic revenue growth.